PDF] KRasG12C inhibitors in clinical trials: a short historical perspective† †Electronic supplementary information (ESI) available. See DOI: 10.1039/d0md00096e | Semantic Scholar
Ongoing clinical trials involving direct targeting of KRAS. | Download Scientific Diagram
World Lung 2019 – Amgen tries to keep the pace in Kras chase | Evaluate
Enhanced binding of AMG 510 to KRAS(G12C) results in improved... | Download Scientific Diagram
Asco 2019 – KRAS chase heats up with Amgen data | Evaluate
The Discovery Of Amgen's Novel Investigational KRAS(G12C) Inhibitor AMG 510 Published In Nature
Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors | Journal of Medicinal Chemistry
Sotorasib: a KRASG12C inhibitor for non-small cell lung cancer: Trends in Pharmacological Sciences
SHP2 and SOS1 Targets: Additional Players in the KRAS Inhibitors Race?
Mixed data: AMG 510 in tumours with KRASG12C - Medical Conferences
Amgen's AMG 510 Targeted Cancer Therapy (NASDAQ:AMGN) | Seeking Alpha
Amgen unveils its KRas inhibitor in human clinical trials